Remote Approaches for Evaluating Clinical Site Capabilities During Feasibility

Introduction: Shifting from On-Site to Remote Capability Assessments

The COVID-19 pandemic accelerated the adoption of remote and digital approaches in clinical research operations, including feasibility assessments and site qualification. Even post-pandemic, the use of remote methods to evaluate clinical site capabilities remains highly relevant due to cost savings, operational flexibility, and global trial complexity. Sponsors and CROs now conduct virtual site evaluations using teleconferencing, document sharing platforms, e-questionnaires, and remote facility walkthroughs to determine site readiness for clinical trials.

These remote methods must still comply with regulatory expectations and Good Clinical Practice (GCP) guidelines, while ensuring that sponsors adequately assess investigator qualifications, infrastructure, SOPs, technology readiness, and enrollment feasibility. This article provides a structured overview of remote methods for evaluating site capabilities, including benefits, limitations, digital tools, documentation practices, and best practices for inspection readiness.

1. Scope and Objectives of Remote Site Capability Assessments

Remote site assessments serve the same core purposes as on-site audits:

• Confirming investigator qualifications and experience
• Evaluating staffing, infrastructure, and SOP availability
• Reviewing technology readiness (e.g., EDC access, eConsent tools)
• Assessing enrollment potential and competing trial burden
• Ensuring regulatory and ethics committee preparedness

Remote assessments may be conducted as the sole method of feasibility or as a supplement to on-site audits, especially in decentralized, global, or hybrid trials.

2. Digital Tools and Platforms for Remote Evaluation

Several technologies enable effective remote feasibility and capability assessments:

• eFeasibility Platforms: Centralized systems for sending, collecting, and analyzing feasibility questionnaires (e.g., Clario, Veeva, TrialHub)
• Video Conferencing Tools: Used for live PI and staff interviews (e.g., Zoom, Microsoft Teams, Webex)
• Secure Document Sharing: For reviewing SOPs, CVs, calibration logs, and training records (e.g., SharePoint, Box, Dropbox Business)
• Virtual Facility Tours: Pre-recorded videos or live walkthroughs to inspect clinical and pharmacy areas
• Digital Signature Tools: For validating signed documents (e.g., DocuSign, Adobe Sign) compliant with 21 CFR Part 11

These tools must be validated where applicable and aligned with data privacy laws such as GDPR or HIPAA.

3. Components of a Remote Site Capability Assessment

During a remote feasibility process, sponsors should evaluate the following elements:

3.1 Investigator Qualifications and Oversight

• Request signed and dated CVs with therapeutic area experience
• Confirm GCP training within the past 24 months
• Schedule video interviews with PI and study coordinator
• Assess time allocation for trial and competing study load

3.2 Staffing and Infrastructure Review

• Request staffing matrix and delegation of duties template
• Collect site organizational chart and training logs
• Review equipment inventory and calibration certificates remotely
• Conduct virtual tour of IP storage room, exam rooms, lab areas

3.3 SOP and Quality Systems Documentation

• Request SOP index and sample SOPs (e.g., AE reporting, IP handling)
• Verify approval dates, version control, and review cycles
• Check SOP training records and acknowledgment logs

3.4 Technology Readiness

• Test access to sponsor platforms (EDC, IRT, eTMF)
• Verify internet stability and data security practices
• Assess familiarity with remote monitoring tools
• Ensure compatibility with eConsent, ePRO, and telehealth systems

3.5 Ethics Committee and Regulatory Preparedness

• Request past EC approval letters with turnaround times
• Confirm IRB registration status and contact details
• Discuss submission cycles and review schedules
• Clarify local regulatory steps, especially for global sites

4. Sample Remote Audit Summary Table

5. Regulatory Compliance in Remote Feasibility

Remote assessments must meet the same GCP and documentation requirements as in-person evaluations. Regulatory expectations include:

• Maintaining documented evidence of all remote assessments
• Version-controlled checklists and signed audit summaries
• Secure transmission and storage of shared files
• Recording video calls where permitted and logging attendance
• Ensuring systems used are Part 11 / Annex 11 compliant where applicable

The FDA, EMA, and MHRA have all published guidance supporting remote monitoring and oversight, especially in hybrid and decentralized models. Tools and processes used must be included in the sponsor’s TMF and internal SOPs.

6. Advantages of Remote Site Capability Assessments

• Cost-effective, especially for global and emerging markets
• Faster scheduling and turnaround time
• Enables review of more sites during early-stage feasibility
• Reduces travel burden and carbon footprint
• Supports decentralized trial models

7. Challenges and Limitations

• May miss facility details not visible via video
• Some sites lack technical capability or digital experience
• Potential data privacy risks during document sharing
• Subjective assessment of cleanliness, temperature logs, equipment state

Remote assessments may not fully replace on-site visits, especially for high-risk or first-time sites. A hybrid model may be more appropriate in such cases.

8. Best Practices for Remote Feasibility Teams

• Use a standardized remote audit checklist with clear pass/fail criteria
• Schedule structured video calls with predefined agenda
• Assign a tech coordinator to assist the site with video tours or file uploads
• Maintain a real-time tracker of document receipt and pending actions
• Ensure all activities are logged and archived in TMF with access audit trails

9. Real-World Example: Remote Assessment in Asia-Pacific Region

In a Phase III vaccine trial, a sponsor used remote feasibility methods to assess 28 sites across India, Vietnam, and Malaysia. The sponsor deployed eFeasibility tools and conducted structured Zoom interviews. While 5 sites were excluded due to lack of cold chain documentation or poor internet access, 23 were qualified and activated within 21 days—70% faster than previous trials. Remote methods enabled quick rollout while maintaining compliance and quality.

Conclusion

Remote methods for evaluating clinical site capabilities offer a flexible, scalable, and cost-effective alternative to traditional on-site audits. With the right tools, structured procedures, and documentation controls, sponsors and CROs can ensure a thorough and compliant feasibility process that supports modern clinical trial models. As digital trials continue to expand, remote feasibility will remain a core competency for clinical operations and regulatory teams alike.

How AI-Based Feasibility Tools Are Transforming Site Selection

Introduction: The Limitations of Traditional Feasibility Methods

Clinical trial site selection has traditionally relied on manual feasibility questionnaires, investigator self-reporting, and subjective decision-making by sponsor teams. These legacy methods are often inconsistent, time-consuming, and vulnerable to bias. They fail to leverage the enormous amount of historical and real-time data now available in clinical trial systems, EHRs, and public registries.

As trials grow more complex and global, sponsors need more accurate, data-driven methods to select sites that will meet recruitment targets, adhere to protocols, and pass regulatory scrutiny. Enter artificial intelligence (AI): advanced algorithms capable of analyzing vast datasets to predict which sites are most likely to perform. AI-based feasibility tools are transforming the way sponsors plan, score, and validate site selection decisions.

This article examines how AI is being applied to feasibility in clinical trials, the core functionalities of AI-driven tools, benefits for sponsors and CROs, regulatory considerations, and case studies of successful implementation.

What Are AI-Based Feasibility Tools?

AI-based feasibility tools are platforms or modules that use machine learning algorithms to analyze structured and unstructured data sources to evaluate site capabilities. These tools help predict:

• Likelihood of patient recruitment success
• Protocol deviation risk
• Startup speed and regulatory approval timelines
• Data quality and eCRF completion compliance

Some tools also integrate natural language processing (NLP) to scan free-text site responses, investigator CVs, or prior inspection reports to uncover potential red flags.

Example vendors and tools include:

• TrialHub: Combines historical site performance with real-world epidemiological data
• SiteIQ (IQVIA): Uses predictive modeling based on global site benchmarking
• Antidote Match: Uses AI to match patients to studies and model site potential

Data Sources Used in AI Feasibility Models

AI-based feasibility platforms aggregate data from numerous sources to fuel their predictive engines:

For example, a site may self-report a capacity to recruit 60 patients for a metabolic trial. An AI tool might access EHR data, recognize only 20 qualified patients in the database, and flag this discrepancy for manual review—improving selection accuracy.

Publicly available registries such as Canada’s Clinical Trials Database can also be integrated for validation purposes.

Core Functionalities of AI-Based Site Selection Platforms

AI feasibility tools typically include several key modules:

• Predictive Enrollment Modeling: Analyzes patient population and prior enrollment speed
• Feasibility Scoring Engines: Generates composite scores based on predefined KPIs
• Automated Questionnaire Review: Uses NLP to detect inconsistencies or gaps
• Risk Ranking: Categorizes sites by low/medium/high risk for deviations or noncompliance
• Dynamic Dashboards: Visualize site performance, regulatory readiness, and projected ROI

These platforms often integrate into CTMS and eTMF systems, allowing sponsors to move directly from feasibility to activation workflows.

Benefits of Using AI in Feasibility Planning

Adopting AI-based feasibility solutions brings measurable improvements:

• Reduced site activation time by 20–40%
• Lower protocol deviation rates
• Better enrollment forecasting accuracy
• Centralized, audit-ready documentation of decisions
• Objective and reproducible site selection process

In addition, AI tools reduce the reliance on subjective site self-assessments, which have historically led to overestimated recruitment capabilities and inconsistent site performance.

Regulatory Considerations and Compliance

While AI tools provide operational advantages, they must align with regulatory expectations for site selection documentation. Regulatory guidelines from the FDA, EMA, and ICH GCP specify:

• Sponsors must document how and why a site was selected
• Tools used must be validated and audit-ready
• Site scoring models should be reproducible and transparent
• Electronic records must comply with 21 CFR Part 11 and Annex 11

Sponsors using AI should retain documentation of algorithm logic, input data sources, risk scores, and any manual overrides. These materials must be made available during audits and inspections.

Challenges and Limitations

Despite the advantages, several challenges must be addressed:

• Data privacy concerns, especially in EHR integrations (GDPR compliance)
• Bias in historical data used to train AI models
• Limited AI adoption in certain regulatory environments
• Cost of implementation and platform validation
• Need for human oversight to interpret AI-generated outputs

These can be mitigated through hybrid models combining AI recommendations with expert review, robust SOPs for AI-assisted feasibility, and use of explainable AI models with transparent logic.

Case Study: Oncology Trial Using AI Feasibility Scoring

In a recent global Phase III oncology trial, the sponsor deployed an AI feasibility platform across 120 potential sites. Key outcomes:

• ➤ 32% reduction in average site startup time
• ➤ 18% increase in patient enrollment rates
• ➤ 25% fewer protocol deviations from selected sites
• ➤ All site selection decisions were documented and passed regulatory audit

The platform integrated CTMS and external registry data, flagged 14 sites as high-risk, and prioritized 60 low-risk, high-potential sites. This enabled resource optimization and stronger trial performance metrics.

Best Practices for Implementing AI-Based Feasibility Tools

• Start with a pilot study to validate tool accuracy and user acceptance
• Document all model assumptions, logic, and scoring weights
• Train feasibility and QA teams in interpreting AI outputs
• Ensure data security, consent, and privacy compliance
• Create audit trail reports for all AI-generated recommendations

Conclusion

AI is rapidly changing the way feasibility assessments and site selection are conducted in clinical research. By analyzing historical and real-time data, AI tools can predict site performance with higher accuracy, reduce risk, and improve compliance. Sponsors and CROs that embrace AI-powered feasibility tools position themselves to execute faster, more cost-effective, and regulatorily sound trials. As these tools evolve, they will become integral to the digital transformation of global clinical trial operations.